A Phase 1, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors
Latest Information Update: 29 Apr 2024
At a glance
- Drugs AGENT-797 (Primary) ; Nivolumab; Pembrolizumab
- Indications Biliary cancer; Cervical cancer; Cholangiocarcinoma; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer; Renal cancer; Solid tumours; Testicular cancer; Urogenital cancer; Uveal melanoma
- Focus Adverse reactions
- Sponsors MiNK Therapeutics
- 22 Apr 2024 Status changed from recruiting to completed.
- 30 Jan 2024 According to a MiNK Therapeutics media release, data from this study published as a case report in Oncogene Journal.
- 30 Jan 2024 Results presented MiNK Therapeutics in the Media Release.